MX9304056A - Compuestos para el tratamiento de padecimientos neoplasticos. - Google Patents

Compuestos para el tratamiento de padecimientos neoplasticos.

Info

Publication number
MX9304056A
MX9304056A MX9304056A MX9304056A MX9304056A MX 9304056 A MX9304056 A MX 9304056A MX 9304056 A MX9304056 A MX 9304056A MX 9304056 A MX9304056 A MX 9304056A MX 9304056 A MX9304056 A MX 9304056A
Authority
MX
Mexico
Prior art keywords
neoplastic
treatment
substrate
compounds
sufferings
Prior art date
Application number
MX9304056A
Other languages
English (en)
Inventor
Timothy Alan Shepherd
Victor John Chen
Louis Nicholaus Jungheim
Damon Lawrence Meyer
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of MX9304056A publication Critical patent/MX9304056A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un método para el tratamiento de enfermedades neoplásticas o neoplásicas, que comprende: a) administrar una cantidad terapéuticamente efectiva de un conjugado de Anticuerpo-Enzima al huésped afectado; y luego b) administraruna cantidad terapéuticamente efectiva de un Substrato-Agente Citotóxico al huésped afectado, en donde el Substrato es un substrato para la Enzima. También se describen conjugados de Anticuerpo-Enzima y compuestos de Substrato-Agente Citotóxico.
MX9304056A 1992-07-06 1993-07-06 Compuestos para el tratamiento de padecimientos neoplasticos. MX9304056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90992492A 1992-07-06 1992-07-06

Publications (1)

Publication Number Publication Date
MX9304056A true MX9304056A (es) 1994-05-31

Family

ID=25428053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304056A MX9304056A (es) 1992-07-06 1993-07-06 Compuestos para el tratamiento de padecimientos neoplasticos.

Country Status (6)

Country Link
CN (1) CN1087642A (es)
AU (1) AU4663493A (es)
IL (1) IL106228A0 (es)
MX (1) MX9304056A (es)
WO (1) WO1994001137A1 (es)
ZA (1) ZA934825B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025061A1 (en) * 1993-04-23 1994-11-10 Glyko, Inc. Methods and compositions for treating diseases with carbohydrate modifying enzymes
US5928888A (en) * 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
ATE123414T1 (de) * 1989-01-23 1995-06-15 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof

Also Published As

Publication number Publication date
WO1994001137A1 (en) 1994-01-20
IL106228A0 (en) 1993-11-15
CN1087642A (zh) 1994-06-08
ZA934825B (en) 1995-01-05
AU4663493A (en) 1994-01-31

Similar Documents

Publication Publication Date Title
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
AR033796A1 (es) Composicion farmaceutica
AU537874B2 (en) Polyacrylate topical pharmaceutical
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
AU4373993A (en) Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
AR032293A1 (es) Estuche farmaceutico
ES483511A1 (es) Un procedimiento para la preparaion de nuevas espiro-oxazo- lidinohoinas.
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
PT93959A (pt) Processo para a preparacao de derivados de sacarina uteis como inibidores proteoliticos de enzima
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
ATE114974T1 (de) Abgabe von cytotoxischen mitteln.
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
MX9304056A (es) Compuestos para el tratamiento de padecimientos neoplasticos.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DE69635806D1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion